Kolosis BIO (Kolosis), a leading provider of biologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are excited to announce their partnership in the surgical incision market.
Kolosis BIO (Kolosis), a leading provider of orthobiologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are proud to announce the extension of their successful partnership.
Kolosis BIO, LLC (Kolosis), a pure-play biologics company and an exclusive bone graft partner to MTF Biologics, announced today its 2022 results and 2023 expectations.
Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Charles Crockett as Area Vice President of Sales, East.
Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Michelle Soleimani-Mafi as its Director of Operations.
Kolosis BIO, LLC (Kolosis), a pure-play orthobiologics company and an exclusive partner to MTF Biologics, announced today its 2021 results and 2022 expectations.
Salt Lake City, Utah, – Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the relocation of its global headquarters to the historic Seed Building in downtown Salt Lake City.
Kolosis BIO, a privately-held pure-play orthobiologics company, announces its support of the 2022 Montana Orthopedic Society meeting, January 14-16 at the Yellowstone Conference Center in Big Sky, Montana.
Salt Lake City, Utah – Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the completion and release of a scientific white paper studying the effects of terminal sterilization on allograft tissues.
